RE:RE:RE:RE:RE:New Corporate Presentation is up Is this an efficacy study or are they just showing bio-equivalence type studies, showing IM has same pharmaco profile as IV?
Spartrap wrote:
Well I assumed "conducted" (footnotes on page 6 and 7) meant TH is footing the bill.
Maybe not, or maybe costs are shared..but then wouldn't the corporate document make that unambiguous?
SPCEO1 wrote: Where did you see that TH is footing the bill for the IM Trogarzo trial?
Spartrap wrote: Was it known that the Trogarzo's IM study is to be conducted by Thera?
Wonder how much this is going to cost, on top of the two other european trog studies.. (ouch)
scarlet1967 wrote:
For R&D looking through it quickly they added the fast track for PDC and study may proceed for both protocols.
The commercializing strategies seems to have few new additions, note they are saying the Trogarzo market opportunity could be as much as US!
“New Go-to-Market Strategy Underpinned by Sales Force Reorganization and Targeted Patient / Prescriber Education.
Leverage existing localized KOL relationships to capture HIV market opportunities, which could scale to parity with the U.S.
Targeted and frequent educational initiatives to key KOLs, patients and the HIV community.”
SPCEO1 wrote: https://www.theratech.com/wp-content/uploads/2021/03/Corporate-Presentation_Theratehnologies_March-2021.pdf